mRNA Cancer Vaccines Activate a Backup Immune Pathway, Washington University Study Finds

The assumption was straightforward: mRNA cancer vaccines work by activating type 1 conventional dendritic cells, known as cDC1s, and those cells prime the CD8+ T cells that hunt tumors. Turns out that's not the whole story.

A Washington University School of Medicine team published a study April 15 in Nature showing that mRNA cancer vaccines retain their tumor-killing power even when cDC1s are completely absent from the mouse model. The paper, titled "mRNA vaccines engage unconventional pathways in CD8+ T cell priming" and led by senior authors Kenneth M. Murphy and William E. Gillanders, identifies what the team calls an alternative or backup pathway.

<cite index="8-15,8-16">Even without cDC1 cells, the mRNA vaccine still triggered strong cancer-killing responses in mice, because a closely related dendritic cell subtype, cDC2, can also stimulate anti-tumor immune activity. That was unexpected, given that this related subtype isn't involved in responses to conventional vaccines.</cite>

<cite index="10-2,10-3">Mice vaccinated with the mRNA cancer vaccine generated strong T cell responses without cDC1s, and those same mice were able to eliminate sarcoma tumors.</cite> Sarcomas, hard-to-treat connective tissue cancers, are one of the harder benchmarks in preclinical immunotherapy work, so the clearance result matters.

<cite index="9-8,9-9">More specifically, cDC1s and cDC2s generate T cells with distinct molecular profiles, and both cell types contribute to mRNA vaccine efficacy against tumors.</cite> That's not a small biological footnote. It means the immune response these vaccines produce is likely more diverse in character than previous models predicted, which could help explain why some patients in clinical trials respond more strongly than others.

<cite index="13-1">The findings give researchers concrete targets for making future mRNA cancer vaccines more effective, according to co-author Gillanders.</cite> <cite index="13-2">The results could improve vaccine formulation and dosing, potentially explain patient-to-patient variation in vaccine response, and guide strategies for boosting vaccine efficacy.</cite>

The context here is worth keeping clear. <cite index="10-8">The same mRNA technology used during COVID-19 is now being adapted to fight cancer, with experimental mRNA vaccines already being tested against melanoma, small cell lung cancer, bladder cancer, and several other cancers.</cite> That pipeline makes a mechanistic finding like this one unusually actionable: clinical trial designers can start asking whether vaccine formulations that deliberately recruit both cDC1 and cDC2 populations perform better.

<cite index="6-8">This is preclinical research; it does not represent an approved treatment.</cite> The study's mouse models can't account for the full complexity of the human immune landscape, tumor microenvironments vary enormously between cancer types, and a backup pathway demonstrated in engineered knockout mice hasn't been confirmed in human patient samples. The EurekAlert release from Washington University School of Medicine reviewed for this article doesn't report effect sizes for the human-relevant outcomes, because those measurements weren't the study's scope.

What the paper does do is establish a mechanistic foundation that applied teams can now test. If deliberate co-activation of both dendritic cell subtypes moves a tumor-clearance curve in a non-human primate model, the argument for a reformulation strategy in ongoing human trials becomes much easier to make. That's the kind of upstream biology work the field has needed, and it's a more durable contribution than any single trial result.

Sources cited:
- Nature (via EurekAlert / Washington University School of Medicine) (https://www.eurekalert.org/news-releases/1124555)
- News-Medical.net coverage of the Nature paper (https://www.news-medical.net/news/20260417/Scientists-find-unexpected-immune-pathways-for-mRNA-cancer-vaccines.aspx)
- WashU Medicine, The Source (https://source.washu.edu/2026/04/mrna-vaccines-follow-unconventional-immune-path-to-destroy-tumors/)
- ScienceDaily writeup (July 8, 2026) (https://www.sciencedaily.com/releases/2026/07/260708022212.htm)
- MedicalXpress summary with full citation (https://medicalxpress.com/news/2026-04-mrna-cancer-vaccines-destroy-tumors.html)